Jacob G. Appelbaum, Ph.D., Founder and CEO Dr. Appelbaum is a theoretical physicist and biophysicist with broad interests ranging from particle accelerators for security, medical and industrial applications to nanotechnology in applications to antiviral and anticancer therapeutics. His strong background in protein chemistry and molecular biology allowed him to make significant contributions to the further advancement of a novel approach to treatment of viral diseases originally proposed by Dr. Rudolph I. Salganik. Dr. Appelbaum has authored and co-authored over 70 scientific papers and three U.S. patent applications. Dr. Appelbaum together with Dr. Salganik is a co-inventor of the antiviral technology assigned to Avirid Biotechnology, LLC. From 1991 to the present Dr. Appelbaum has been a consultant with U.S. and European multinationals including Eastman Kodak, Polaroid, Emergency-One, Oregon Freeze Dry, Bord Na Mona, Olivetti Group, Scientific-Atlanta, Textron, and others. Dr. Appelbaum has also served as a consultant to the U.S. Department of Defense, NASA, Jet Propulsion Laboratory (JPL), California Institute of Technology, MIT and the Universities of California, Florida, Florida State, Maryland and North Carolina. His consulting services have included management of R&D programs, technology evaluation and acquisition, manufacturing assessment, joint venture development and strategic marketing in Eastern Europe and Russia. Dr. Appelbaum is a member of the American Association for Advancement in Science (AAAS), International Society for Antiviral Research (ISAR), American Physical Society, American Chemical Society and The New York Academy of Sciences. Dr. Appelbaum is an experienced entrepreneur. He was the founder and president of Advanced Technology Development, Inc., a technology development and consulting company since 1992. He was the founder of Security Screening Systems, Inc. (S-3) in 2004, a developer of ultra-low dose radiographic imaging systems for security screening of personnel. He was a co-founder and VP-Business Development of Wireless Network Technologies, Inc. (WNT) of Vienna, VA, a satellite telecommunication service provider from 1993 until its acquisition in 1995, and he was a co-founder and president of Swimming Innovations, Inc. (SI), a developer of swimming accessories for the disabled from 1988 until its acquisition in 1992. Education and Academic Career:   1978: Ph.D. in Theoretical and Applied Physics, Budker Institute of Nuclear Physics (BINP), Russian Academy of Sciences, Novosibirsk, Russia.   1988 - 1992: Research Professor, Innovative Nuclear Space Power Institute, College of Engineering, University of Florida, Gainesville, Florida.   1987 - 1988: Senior Research Scientist, College of Engineering, California State University, Long Beach, California.   1974-1983: Senior Research Scientist, Budker Institute of Nuclear Physics and Institute of Automation and Electrometry of the Russian Academy of Sciences, Novosibirsk, Russia. Rudolph I. Salganik, Ph.D., D.Sc., M.D., Chief Scientific Officer Dr. Salganik is a renowned biochemist with a strong background in molecular genetics. He was recipient of the four highest national awards in the former Soviet Union - Lenin's Prize in 1990, the Soviet Union State Prize in 1988, Order of Red Banner in 1983, and Order of Red Banner in 1967 for his scientific achievements in the fields of molecular biology and biochemistry. He was elected as an Active Member (Academician) of the Russian Academy of Sciences (RAS) in 1992 and was a Corresponding Member of RAS since 1982. Since his immigration to the US in 1994 Dr. Salganik has served as Research Professor at the College Medicine of the University of North Carolina at Chapel Hill. His breakthrough in cancer treatment - inducing apoptosis in cancer cells by utilizing a special antioxidant-depleted diet was announced as a major discovery in cancer at the 1999 American Society for Cell Biology meeting. Recently Dr. Salganik has been invited to present a lecture on "Targeted Anticancer Apoptosis - a Natural Magic Bullet" at the "World and Ehrlich Conference on Magic Bullets", a prestigious scientific conference held on the occasion of Paul Ehrlich's 150th birthday on September 9-12, 2004 in Nuremberg, Germany. Dr. Salganik served as a Member of the Steering Committee and Special Advisor to the World Health Organization (WHO) during 1988-1991. Dr. Salganik published 325 papers in scientific journals and books and is a co-authored 15 Russian and one US patents, additional two US patents are pending. Dr. Salganik's scientific interests include molecular physiology and pathology, more specifically molecular mechanisms of cellular mutagenesis and carcinogenesis, and molecular mechanisms of hormone activities. The discoveries of the molecular mechanisms of viral replication prompted his early work on antiviral compounds that directly impair viral nucleic acids and inhibit viral replication. Recently Dr. Salganik together with Dr. Appelbaum developed new broad-spectrum antiviral therapeutics and method of treatment of viral diseases that overcome viral drug resistance. Dr. Salganik was among the first biological scientists who developed methods of gene-directed mutagenesis and revealed the pathways of double-stranded DNA breaks leading to genomic rearrangements. Together with colleagues, Dr. Salganik suggested new means for the addressed inhibition of transcription. In connection with his work for WHO, he suggested a new approach to overcome the drug-resistance of malarial parasite. In early 1990s he developed a rat strain with an inherited over generation of reactive oxygen species (ROS), mimicking human degenerative diseases such as cataracts, carcinogenesis and impairment of long-term memory. These studies promoted his interest to the role of ROS in carcinogenesis. Being invited to work at the Department of Nutrition, University of North Carolina at Chapel Hill in 1995, he concentrated his efforts on the relation between cancer development, ROS and programmed cell death (apoptosis). At that time it was becoming evident that ROS can induce apoptotic death of cancer cells. However, to bring ROS to cancer cells was not possible in view of the delivery problems and their very short life span. Dr. Salganik suggested that the selective induction of apoptosis in cancer cells can be achieved by temporary removal of dietary antioxidants which act as ROS scavengers. Experiments carried out by Dr. Salganik together with Drs. Craig Albright and Terry Van Dyke in the University of North Carolina at Chapel Hill have demonstrated that antioxidant-depleted diet provided high-level of apoptosis selective to cancer cells and significant reduction in the size of brain and mammary tumors in transgenic mice. Prior to his emigration from Russia, Dr. Salganik served as Deputy Director on Research and Head of the Molecular Genetics Department in the Institute of Cytology and Genetics (IC&G) of the Russian Academy of Sciences in Novosibirsk, Russia, where he supervised the research of over 60 Ph.D. scientists. He also served as Professor of Biochemistry and Molecular Biology, Department of Molecular Biology, Novosibirsk State University, Russia. Dr. Salganik co-founded two biotechnology companies in Russia and served as a senior executive at both companies: BioStart founded in 1978 and BioSib founded in 1986. BioStart, later renamed the Institute of Biotechnology, was the first Russian biotechnology company engaged in the commercial development and production of genetic and protein derived products for research and industrial markets. Education and Academic Career:   1966: D.Sc. in Molecular Biology, Institute of Cytology and Genetics of the Russian Academy of Sciences (IC&G RAS), Novosibirsk, Russia.   1958: Ph.D., Biochemistry, University of Rostov, Rostov, Russia.   1956: M.D., Moscow Medical University, Moscow, Russia.   1994-present Research Professor, Department of Nutrition, University of North Carolina at Chapel Hill.   1974-1994: Deputy Director on Research and Head of the Department of Molecular Genetics, IC&G RAS   1988-1991: Member of the Steering Committee and Scientific Advisory Board, World Health Organization, Geneva   1972-1994: Professor of Biochemistry and Molecular Biology, Department of Molecular Biology, Novosibirsk State University, Russia